Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.35 |
| ▸ | BRD4 | O60885 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863631 | 0.96 | PARK7 (0.42) | PARK7MMP2RECQLMCL1PSEN1 | |
| SCHEMBL4867578 | 0.91 | MMP2 (0.40) | PARK7MMP2PSEN1PSEN2APH1B | |
| SCHEMBL4863678 | 0.89 | MMP2 (0.38) | MMP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4865611 | 0.89 | MMP2 (0.38) | PARK7MMP2RECQLPSEN1PSEN2 | |
| SCHEMBL4871154 | 0.89 | MMP2 (0.50) | PARK7MMP2 | |
| SCHEMBL4867899 | 0.88 | BRD4 (0.42) | MMP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4870419 | 0.88 | MMP2 (0.42) | MMP2BRD4ESR1 | |
| SCHEMBL4862003 | 0.88 | PARK7 (0.43) | PARK7MMP2RECQLMCL1PSEN1 | |
| SCHEMBL4867661 | 0.87 | MMP2 (0.41) | MMP2RECQLESR1 | |
| SCHEMBL4869269 | 0.85 | MMP2 (0.42) | MMP2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | claimed |
| US-7351709-B2 | Estrogen receptor ligands | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20060019961-A1 | Estrogen receptor ligands | WYETH | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019961-A1 | Estrogen receptor ligands | GPER1, ESR2, ESR1 | PARK7 4572/4885MMP2 2599/4885RECQL 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.